RT Journal Article
SR Electronic
T1 PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.06.22274705
DO 10.1101/2022.05.06.22274705
A1 Oldham, Justin M.
A1 Allen, Richard J.
A1 Lorenzo-Salazar, Jose M.
A1 Molyneaux, Philip L.
A1 Ma, Shwu-Fan
A1 Joseph, Chitra
A1 Kim, John S.
A1 Guillen-Guio, Beatriz
A1 Hernández-Beeftink, Tamara
A1 Kropski, Jonathan A.
A1 Huang, Yong
A1 Lee, Cathryn T.
A1 Adegunsoye, Ayodeji
A1 Pugashetti, Janelle Vu
A1 Linderholm, Angela L.
A1 Vo, Vivian
A1 Strek, Mary E.
A1 Jou, Jonathan
A1 Muñoz-Barrera, Adrian
A1 Rubio-Rodriguez, Luis A.
A1 Hubbard, Richard
A1 Hirani, Nik
A1 Whyte, Moira K.B.
A1 Hart, Simon
A1 Nicholson, Andrew G.
A1 Lancaster, Lisa
A1 Parfrey, Helen
A1 Rassl, Doris
A1 Wallace, William
A1 Valenzi, Eleanor
A1 Zhang, Yingze
A1 Mychaleckyj, Josyf
A1 Stockwell, Amy
A1 Kaminski, Naftali
A1 Wolters, Paul J.
A1 Molina-Molina, Maria
A1 Fahy, William A.
A1 Martinez, Fernando J.
A1 Hall, Ian P.
A1 Tobin, Martin D.
A1 Maher, Toby M.
A1 Blackwell, Timothy S.
A1 Yaspan, Brian L.
A1 Jenkins, R Gisli
A1 Flores, Carlos
A1 Wain, Louise V
A1 Noth, Imre
YR 2022
UL http://medrxiv.org/content/early/2022/05/07/2022.05.06.22274705.abstract
AB Rationale Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by limited treatment options and high mortality. Novel therapies and prognostic biomarkers are needed.Objective To identify and validate molecular determinants of IPF survival.Methods A staged genome-wide association study (GWAS) was performed using paired genomic and survival data. Stage I cases were drawn from centers across the US and Europe and stage II cases from Vanderbilt University. Cox proportional hazards regression was used to identify gene variants associated with differential transplant-free survival (TFS). Stage I variants with nominal significance (p<5×10−5) were advanced for stage II testing and meta-analyzed to identify those reaching genome-wide significance (p<5×10−8). Downstream analyses were performed for genes and proteins associated with variants reaching genome-wide significance.Main Results After quality controls, 1481 stage I cases and 397 stage II cases were included in the analysis. After filtering, 9,075,629 variants were tested in stage I, with 158 meeting advancement criteria. Four variants associated with TFS with consistent effect direction were identified in stage II, including one in an intron of proprotein convertase subtilisin/kexin type 6 (PCSK6) reaching genome-wide significance (HR 4.11; 95%CI 2.54-6.67; p=9.45×10−9). PCSK6 protein was highly expressed in IPF lung parenchyma and negatively correlated with survival. Peripheral blood PCSK6 gene expression and plasma concentration were associated with reduced transplant-free survival.Conclusions We identified four novel variants associated with IPF survival, including one in PCSK6 that reached genome-wide significance. Downstream analyses suggested that PCSK6 protein may serve as prognostic biomarker in IPF and potential therapeutic target.Competing Interest StatementJMO reports grants from the National Heart, Lung, and Blood Institute (NHLBI), American Lung Association and American Thoracic Society related to the submitted work and personal fees from Genentech, Boehringer Ingelheim, United Therapeutics, Lupin pharmaceuticals and AmMax Bio unrelated to the submitted work. PLM has received industry-academic funding from AstraZeneca and GSK and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche outside the submitted work. JSK reports grants from the NHLBI and Pulmonary Fibrosis Foundation. AGN reports consultancy fees for Galapagos, Medical Quantitative Image Analysis and Boehringer Ingelheim, and fees for educational activities from Boehringer Ingelheim and UptoDate. AA reports grants from the National Heart, Lung, and Blood Institute (NHLBI), American College of Chest Physicians, and the Pulmonary Fibrosis Foundation, and speaking and advisory board fees from Genentech and Boehringer Ingelheim. MES has received grants from Boehringer Ingelheim and Galapagos and personal fees from Boehringer Ingelheim and Fibrogen. HP reports grants from Roche; personal fees from Boehringer Ingelheim, Roche and Pliant Therapeutics and is a Trustee for the charity Action for Pulmonary Fibrosis. IPH holds an NIHR Senior Investigator Award. AS and BLY are employees of Roche/Genentech with stock and stock options in Roche. TMM has received industry-academic funding from GlaxoSmithKline (GSK) R&D and UCB; and has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GSK R&D, InterMune, ProMetic, Roche, Sanofi-Aventis, Sanumed, and UCB. IN reports personal fees and consultancy, advisory board, speaker, and study contracts for Boehringer Ingelheim and Genentech from Boehringer Ingelheim and Genentech; personal fees from Immuneworks, Sanofi Aventis, Global blood therapeutics; and has a patent for Toll-interacting protein (TOLLIP) and pharmacogenetics pending. NK served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira, Astra Zeneca, Veracyte, Augmanity and CSL Behring, over the last 3 years, reports Equity in Pliant and a grant from Veracyte, Boehringer Ingelheim, BMS and non-financial support from MiRagen and Astra Zeneca. NK has IP on novel biomarkers and therapeutics in IPF licensed to Biotech. RGJ reports grants from GSK, UK MRC, Biogen, AstraZeneca, Galecto and NIHR; personal fees from Boehringer Ingleheim, Bristol Myers Squibb, Chiesi, Galapagos, GSK, Heptares, MedImmune, Pharmakea, Roche/Promedior, Pliant Therapeutics, and Veracyte; and is a Trustee for the charity Action for Pulmonary Fibrosis. LVW has received funding from GlaxoSmithKline. All other authors declare no competing interests.Funding StatementNHLBI - K23HL138190 (JMO), R56HL158935 (JMO), K23HL150301 (JSK), K23HL146942 (AA), T32HL007605 (CTL), RO1HL130796 (IN), UG3HL145266 (IN) Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER UE (CF) Instituto de Salud Carlos III co-financed by the ERDF "A way of making Europe" from the EU (PI20/00876, CF), Instituto Tecnologico y de Energias Renovables (OA17/008 (CF) Consejeria de Educacion-Gobierno de Canarias and Cabildo Insular de Tenerife (BOC n.173, 24/08/2017 (JMLS) UK National Institute for Health Research (NIHR) - RGJ holds an NIHR Research Professorship (RP-2017-08-ST2-014) and has MRC grants (G0901226 and MR/V00235X/1). TMM is supported by an NIHR Clinician Scientist Fellowship (NIHR reference CS-2013-13-017). MDT is supported by an NIHR Senior Investigator Award (NIHR201371). The views expressed are our own and not necessarily those of the NHS, the NIHR, or the UK Department of Health. British Lung Foundation Chair in Respiratory Research (C17-3) (TMM), GlaxoSmithKline/British Lung Foundation Chair in Respiratory Research (C17-1) (LWW) Wellcome Trust - WT202849/Z/16/Z (MDT), 221680/Z/20/Z (BGG). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. BREATHE - The Health Data Research Hub for Respiratory Health (MC_PC_19004) (LWW) Action for Pulmonary Fibrosis Research Fellows (RJA and PLM). This research used the ALICE and SPECTRE High Performance Computing Facilities at the University of Leicester and TeideHPC (https://teidehpc.iter.es/en/home) at Instituto Tecnologico y de Energias Renovables.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted using previously published work with appropriate ethics approval. The PROFILE study (which provided samples for the UK and UUS studies) had institutional ethics approval at the University of Nottingham (NCT01134822 - ethics reference 10/H0402/2) and Royal Brompton and Harefield NHS Foundation Trust (NCT01110694 - ethics reference 10/H0720/12). Spanish samples were recruited under ethics approval by ethics committee from the Hospital Universitario N.S. de Candelaria (reference of the approval: PI-19/12). UK samples were recruited across multiple sites with individual ethics approval (University of Edinburgh Research Ethics Committee [The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study NCT04016181] 17/ES/0075, Yorkshire and Humber Research Ethics Committee 08/H1304/54 and Nottingham Research Ethics Committee 09/H0403/59). For individuals recruited at the University of Chicago, consenting patients with IPF who were prospectively enrolled in the institutional review board-approved ILD registry (IRB#14163A) were included. Individuals recruited at the University of Pittsburgh Medical Centre had ethics approval from the University of Pittsburgh Human Research Protection Office (reference STUDY20030223: Genetic Polymorphisms in IPF). This study also included individuals from clinical trials with ethics approval (ACE [NCT00957242], PANTHER [NCT00650091], and COMET [NCT01071707] studies). Individuals for the ACE and PANTHER trials were recruited through the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet, NCT00517933, NCT00650091, NCT00957242), which is a multicentre network recruiting individuals to studies of IPF. Each centre has appropriate ethics approval (IRBs 09-220-B and 09-214-B for the University of Chicago where genotyping of all individuals was conducted), which was overseen by the Duke Clinical Research Institute which acted as the Data Coordinating Centre. For the Vanderbilt cohort, the Institutional Review Boards from Vanderbilt University approved the study and all participants provided written informed consent before enrolment. The tissue samples were obtained after informed consent and local ethics approval (South East Scotland SAHSC Bioresource-reference number 06/S1101/41; Brompton Node samples- reference number 15/SC/0101; Papworth Node Samples reference number 08/H0304/56+5; non-diseased controls-reference number (Q)GM030404 and Nottingham BRC samples- reference number 08/H0407/1).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS Summary statistics for this study can be accessed from https://github.com/genomicsITER/PFgenetics and will be made available at GWAS Catalog